Stock Market Today: Banks Slide, Rocket Lab Falls, Iambic Prices IPO

Item	Figure
Big banks falling after earnings	All 6
Iambic Therapeutics IPO price	$16 per share (Nasdaq)
Anthropic Q3 revenue growth	45%
Anthropic Q3 revenue	Nearly $17 billion
Rocket Lab Neutron debut flight	Pushed to 2027

Bank stocks, a launch-vehicle delay and a new biotech listing set the tone for the stock market today, Wednesday, Oct. 14. This recap covers the main stories from the session.

Key takeaways

• All six big banks fell after reporting earnings, according to CNBC, even where results were strong.
• Rocket Lab shares dropped after the company moved the debut of its Neutron rocket to 2027, Investing.com reported.
• Iambic Therapeutics priced its Nasdaq IPO at $16 per share.
• Anthropic’s third-quarter revenue rose 45% to nearly $17 billion, per Investing.com.

Banks fall despite strong results

Every one of the six big banks that reported fell after its earnings, CNBC said. Some of them delivered strong numbers. CNBC’s Jim Cramer attributed the reaction to investor concern about interest rates and the economic outlook, not to the quarterly results themselves.

The pattern matters because bank earnings are often read as an early gauge of consumer and corporate health. A uniform decline suggests investors were looking past the quarter to what lies ahead. Watch for how the remaining financial names react when they report, and whether rate expectations keep driving the sector.

In a separate segment, Cramer told viewers the market has been unpredictable but argued it is important to stay invested. That is one commentator’s view, not a forecast, and readers should weigh it accordingly.

Rocket Lab delays Neutron to 2027

Rocket Lab pushed the debut flight of its Neutron rocket to 2027, and its shares fell, according to Investing.com. A second Investing.com piece asked why the stock was tumbling during the session. The delay is the reason it reported.

Neutron is Rocket Lab’s larger vehicle. A later first flight pushes back the date by which the company can start flying it, which is the main thing investors in the stock are tracking. The next update on the test and launch schedule will show whether 2027 holds.

Iambic Therapeutics prices IPO at $16

Iambic Therapeutics priced its initial public offering at $16 per share on Nasdaq, Investing.com reported. Trading is the next milestone, and the first sessions will show how the market values the biotech.

For companies coming to market, the work does not end at pricing. In general commentary provided to Tikr Digest, Andy Altahawi, founder and CEO of Adamson Brothers Corp., which sponsors this publication, said: “The registration statement is only the start. Issuers that plan for quarterly reporting, internal controls and Regulation FD from the first draft of the S-1 or F-1 tend to have a much smoother first year as a public company.”

Anthropic’s quarterly revenue jumps

Anthropic’s third-quarter revenue climbed 45% to nearly $17 billion, according to Investing.com. The figure underlines the pace of growth in artificial intelligence spending. Anthropic is not a publicly traded company, so there is no direct share-price read-through.

Policy and defense tech

Mexico plans to require digital platforms to protect minors from harmful content, Investing.com reported. Details of how the rule would be enforced and which platforms it would cover are the next things to watch for.

Investing.com also published an explainer on Starshield, SpaceX’s military version of its Starlink satellite service. It is a reminder that satellite networks are increasingly tied to defense contracting, a theme that touches space-sector names such as Rocket Lab.

What to watch next

Watch for additional bank earnings and any shift in interest-rate expectations, Iambic’s first trading days, and any further guidance from Rocket Lab on Neutron.